Patents
Electroactive materials for stimulation of biological activity of bone marrow stromal cells
Patent Number: 6,190,893This patent is useful for parties interested in altering the biological activity of stromal cells of the bone marrow, particularly in the area of bioengineering. The invention has 5 independent claims. The first covers a method for stimulating biological activities (gene expression, growth, differentiation, transduction, and combo) in bone marrow stromal cells by contacting with an electroactive...
Inventors: Shastri, Venkatram R. (Allston, MA); Rahman, Nahid (Cambridge, MA); Martin, Ivan (Cambridge, MA); Langer, Jr., Robert S. (Newton, MA)
Assignee: Massachusetts Institute of Technology (Cambridge, MA)
Date of First Priority Issue: Friday September 18th, 1998
Hematopoietic cell composition for use in transplantation
Patent Number: 7101708This patent is useful for parties looking to increase bone marrow stem cell homing to areas of need. In normal bone marrow transplants, stem cells from the donor are introduced intravenously and find their way to the bone marrow by virtue of bone marrow-secreted stromal derived factor-1 (SDF-1). It was more recently discovered that following tissue injury (for example stroke and myocardial...
Inventors: Lapidot, Tsvee (Nes-Ziona, IL); Peled, Amnon (Tel-Aviv, IL)
Assignee: Yeda Research and Development Co. Ltd. (Rehovot, IL)
Date of First Priority Issue: Tuesday July 20th, 1999
Two-stage culture protocol for isolating mesenchymal stem cells from amniotic fluid
Patent Number: 7101710This patent useful for parties looking for methodologies to purify mesenchymal stem cells from amniotic fluid. The patent has 3 independent claims. Essentially all three are directed towards a two step culture process where amniotic fluid cells are first grown in a vessel, subsequently non-adherent cells are isolated, and allowed to expand. The difference between the claims is the media used...
Inventors: Tsai, Ming-Song (Taipei, TW); Hwang, Shiaw-min (Hsinchu 300, TW)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Wednesday February 12th, 2003
Methods of isolating hepatic progenitors
Patent Number: 7109028This patent is useful for parties seeking to purify hepatic progenitor cells, or hepatic stem cells. The patent has one independent claim that essentially teaches how to "negatively deplete" a single cell suspension of hepatocytes for all cells except hepatic stem cells. The patent also claims the marker OC3 as expressed on hepatic stem cells. A publication that appears to relate to the...
Inventors: Reid, Lola M. (Chapel Hill, NC); Sigal, Samuel H. (Riverdale, NY); Brill, Shlomo (Ramat-Gan, IL); Holst, Patricia A. (Ossining, NY)
Assignee: Albert Einstein College of Medicine of Yeshiva University (Bronx, NY)
Date of First Priority Issue: Monday July 8th, 1991
2 Comments
2 Comments
Serum-free medium for mesenchymal stem cells
Patent Number: 7109032This patent is useful for parties seeking to expand mesenchymal stem cells, particularly for clinical applications. The invention generally teaches tissue culture media and techniques that alleviate the need for using serum. Since serum is usually from animal origin (fetal calf serum) or in some cases of human origin, there exists possibilities of contaminating cellular sources. The invention...
Inventors: Cancedda, Ranieri (Genoa, IT); Dozin, Beatrice (Rapallo, IT)
Assignee: Consorzio per la Gestione del Centro di Biotecnologie Avanzate (Genoa, IT); Istituto Nazionale per la Ricerca Sul Cancro (Genoa, IT)
Date of First Priority Issue: Thursday September 10th, 1998
Antigen presenting mesenchymal stem cells
Patent Number: 7101704This patent covers mesenchymal and adipocyte lineage cells that have been induced to present exogenous antigen. The patent is useful for companies that are interested in stimulating an immune response through having the mesenchymal or adipocyte-lineage cell to act as an antigen presenting cell. The patent has 2 independent claims. The first covers mesenchymal stem cells that have been treated...
Inventor: Mosca, Joseph (Ellicott City, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Saturday September 20th, 1997
In situ maturation of cultured pancreatic stem cells having a specified, intermediate stage of development
Patent Number: 7101546This invention is useful for treatment of diabetes using encapsulated cells. The invention consists of one independent claim that appears to cover a method for treating diabetes by administration of encapsulated cells that have a specific set of biological and physical properties. The cells appear to be a type of intermediatery cell, or a progenitor cell that is capable of expansion.
Inventors: Tsang, Wen-Ghih (Sherman Oaks, CA); Zheng, Tianli (Culver City, CA); Wang, Yanping (Los Angeles, CA)
Assignee: AmCyte, Inc. (Santa Monica, CA)
Date of First Priority Issue: Wednesday November 21st, 2001
Use of LP82 to treat hematopoietic disorders
Patent Number: 7101539This invention covers the newly discovered cytokine IL-20 and its use in stimulation of proliferation of early, but not differentiated hematopoietic progenitors. The patent is similar to a paper published by one of the authors (Liu L et al. 2003 Nov 1;102(9):3206-9.) The patent has 4 independent claims all directed to use of IL-20 and polypeptides derived from it. The first covers a method of...
Inventors: Heuer, Josef Georg (Indianapolis, IN); Liu, Ling (Carmel, IN); Noblitt, Timothy W. (Fishers, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Date of First Priority Issue: Wednesday February 28th, 2001
Recombinant human alpha-fetoprotein as a cell proliferative agent
Patent Number: 7101837Alpha-fetoprotein (AFP) is a 65-kDa oncofetal glycoprotein found in fetal and maternal fluids during pregnancy and is produced by various types of cancers. This patent is useful for parties seeking methods of inducing proliferation of bone marrow cells. Particularly, AFP may be used to stimulate hematopoiesis in patients, as well as potentially for regenerative applications such as...
Inventor: Murgita, Robert A. (Montreal, CA)
Assignee: Martinex R & D Inc. (Montreal, CA)
Date of First Priority Issue: Tuesday January 24th, 1995
Regulators of the hedgehog pathway, compositions and uses related thereto
Patent Number: 7098196This patent is useful for parties seeking to inhibit signal transduction pathways in stem cells, pathways such as the smoothened-dependent pathway. The patent is primarily important for the treatment of cancer, where one tries to inhibit stem cells that give rise to other tumor cells, although numerous uses in regenerative medicine are also possible. The patent has 5 independent claims, all...
Inventors: Beachy, Philip A. (Ruxton, MD); Chen, James K. (Baltimore, MD); Taipale, Anssi J. (Baltimore, MD)
Assignee: Johns Hopkins University School of Medicine (Baltimore, MD)
Date of First Priority Issue: Wednesday October 13th, 1999